| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -6.1 | -14.6 |
| Net income | -6.1 | -14.6 |
| EPS (diluted, $ a share) | $-1.34 | $-3.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Beacon Topco, Inc.: key numbers
- Shares outstanding
- 100Latest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Beacon Topco, Inc.
All →Beacon Topco M&A Deal with Clywedog Therapeutics, Inc.
Beacon Topco, Inc. entered into a third amendment to its merger agreement with Clywedog Therapeutics, Inc. and Barinthus Biotherapeutics plc. The amendment updates the expected closing timeline and extends the 'End Date' for the merger to November 13, 2026.
- Counterparty
- Clywedog Therapeutics, Inc.
Beacon Topco M&A Deal with Clywedog Therapeutics, Inc.
Beacon Topco, Inc. entered into a second amendment to its merger agreement with Clywedog Therapeutics, Inc., extending the expected closing date and the 'End Date' to October 31, 2026. The filing also disclosed positive Phase 1b clinical trial results for Clywedog's type 2 diabetes candidate, balomenib, which showed sustained glycemic improvement three months after treatment ended.
- Counterparty
- Clywedog Therapeutics, Inc.
Beacon Topco Announces $15M Stock Buyback
Beacon Topco, Inc. launched a cash tender offer to repurchase up to $15 million of its common stock at a price of $6.6609 per share. The offer follows the completion of a transaction where the company acquired Barinthus Biotherapeutics plc via a court-sanctioned scheme of arrangement.
- Value
- $15M